TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT

forecasted

CDC announces available Fiscal Year (FY) 2025 funds to continue complement TB prevention and control and laboratory services and activities at state and local levels to reduce TB morbidity and mortality. The goal of this funding is to prevent transmission of M. tuberculosis (TB) and prevent persons from progressing from latent TB infection to TB disease. Funding levels are determined by formulas reflecting TB disease incidence, case complexity, program performance, and laboratory workload data.Strategies and activities include diagnosis/treatment of persons with TB disease; persons with latent TB infection (LTBI); evaluation of immigrants/refugees with TB or LTBI; targeted testing and treatment of LTBI; program planning, evaluation, and improvement; epidemiologic surveillance and response; human resource development and partnership activities; and public health laboratory strengthening.Expected outcomes include (not limited to): decreases in TB incidence; increases in patients completing treatment within 12 months; increases in TB cases with HIV and drug susceptibility testing results; increases in LTBI testing and treatment completion rates of those who are recommended for treatment; increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data; improvement in turnaround times for specimen receipt and laboratory testing; increases in programs implementing TB elimination plans; and increases in sharing of best practices within and between state/local programs.